Equities analysts predict that Danaher Co. (NYSE:DHR) will report earnings per share of $1.15 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Danaher’s earnings. The highest EPS estimate is $1.16 and the lowest is $1.14. Danaher posted earnings per share of $1.10 during the same quarter last year, which would indicate a positive year over year growth rate of 4.5%. The firm is scheduled to announce its next quarterly earnings report on Thursday, October 17th.
On average, analysts expect that Danaher will report full-year earnings of $4.79 per share for the current year, with EPS estimates ranging from $4.77 to $4.81. For the next fiscal year, analysts expect that the firm will report earnings of $5.59 per share, with EPS estimates ranging from $5.15 to $5.80. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Danaher.
Danaher (NYSE:DHR) last announced its quarterly earnings data on Thursday, July 18th. The conglomerate reported $1.19 EPS for the quarter, beating the Zacks’ consensus estimate of $1.15 by $0.04. The business had revenue of $5.16 billion during the quarter, compared to analyst estimates of $5.09 billion. Danaher had a net margin of 12.22% and a return on equity of 11.53%. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.15 earnings per share.
DHR has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $155.00 price objective (up previously from $142.00) on shares of Danaher in a research report on Friday, July 19th. Argus upped their price objective on shares of Danaher to $165.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Royal Bank of Canada set a $134.00 price objective on shares of Danaher and gave the company a “hold” rating in a research report on Friday, July 19th. Robert W. Baird upped their price objective on shares of Danaher from $131.00 to $148.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. Finally, Wolfe Research initiated coverage on shares of Danaher in a research report on Thursday, May 30th. They issued an “outperform” rating for the company. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $143.54.
Shares of DHR traded down $0.72 during trading hours on Friday, reaching $141.02. 2,109,791 shares of the company traded hands, compared to its average volume of 1,941,115. The stock’s fifty day moving average is $140.14 and its 200 day moving average is $135.23. The stock has a market cap of $100.07 billion, a P/E ratio of 31.20, a price-to-earnings-growth ratio of 2.52 and a beta of 0.94. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.91 and a current ratio of 2.32. Danaher has a 1-year low of $94.59 and a 1-year high of $145.50.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.48%. The ex-dividend date is Thursday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 15.04%.
In other Danaher news, Chairman Mitchell P. Rales purchased 2,500 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average price of $139.52 per share, with a total value of $348,800.00. Following the completion of the transaction, the chairman now directly owns 3,030,453 shares of the company’s stock, valued at approximately $422,808,802.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Daniel L. Comas sold 68,379 shares of the stock in a transaction dated Friday, July 19th. The stock was sold at an average price of $142.05, for a total transaction of $9,713,236.95. Following the completion of the transaction, the executive vice president now directly owns 187,474 shares of the company’s stock, valued at approximately $26,630,681.70. The disclosure for this sale can be found here. Insiders sold 177,202 shares of company stock valued at $25,175,829 in the last three months. Company insiders own 11.40% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wisconsin Investment Board increased its holdings in shares of Danaher by 12.9% during the first quarter. State of Wisconsin Investment Board now owns 692,865 shares of the conglomerate’s stock worth $91,472,000 after buying an additional 79,287 shares in the last quarter. Capital Advisors Ltd. LLC increased its holdings in shares of Danaher by 527.5% during the second quarter. Capital Advisors Ltd. LLC now owns 320 shares of the conglomerate’s stock worth $46,000 after buying an additional 269 shares in the last quarter. Mitchell Capital Management Co. increased its holdings in shares of Danaher by 20.7% during the first quarter. Mitchell Capital Management Co. now owns 12,174 shares of the conglomerate’s stock worth $1,607,000 after buying an additional 2,088 shares in the last quarter. Rehmann Capital Advisory Group increased its holdings in shares of Danaher by 11.1% during the first quarter. Rehmann Capital Advisory Group now owns 2,014 shares of the conglomerate’s stock worth $266,000 after buying an additional 202 shares in the last quarter. Finally, Findlay Park Partners LLP increased its holdings in shares of Danaher by 0.9% during the first quarter. Findlay Park Partners LLP now owns 4,635,000 shares of the conglomerate’s stock worth $611,913,000 after buying an additional 40,000 shares in the last quarter. 78.52% of the stock is owned by institutional investors.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Story: How is a management fee different from a performance fee?
Get a free copy of the Zacks research report on Danaher (DHR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.